Life Matters
Fighting Antibiotic-resistant Bacteria via Biofilm Prevention
Company Overview
Snapshot
Founded in July 2016 by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro, Life Matters operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its biopharmaceutical solutions.
Business overview
Life Matters is a preclinical-stage biopharmaceutical company dedicated to combating antibiotic-resistant bacteria. The company's core technology involves a novel solution that prevents bacterial biofilm growth, thereby making infections more treatable. This approach is particularly relevant for chronic lung infections where biofilm-related P. aeruginosa is a significant factor. Life Matters' small molecules, including its lead product IBF-2, are designed to attenuate biofilm formation without creating resistance, and are effective against a wide range of gram-negative and positive pathogens. The company operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and medical devices.
Log in to access full profile ›Company Intelligence Q&A
- What is Life Matters' primary focus?
- Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria by preventing biofilm formation.
- When was Life Matters founded?
- Life Matters was founded in July 2016.
- Who are the co-founders of Life Matters?
- Life Matters was co-founded by Amit Elbaz, Prof. Robert S. Marks, Karina Golberg, and Prof. Ariel Kushmaro.
- What is the lead product developed by Life Matters?
- Life Matters' lead product is API, IBF-2, a compound with an innovative mechanism of action that attenuates the biofilm mode of growth.
- What problem does Life Matters aim to solve?
- Life Matters aims to solve the problem of antibiotic-resistant bacteria, particularly those acquired in hospitals, by preventing their biofilm mode of growth to make infections more treatable.